FOXP3型
免疫监视
生物
免疫系统
癌症免疫疗法
肿瘤微环境
癌症研究
免疫疗法
免疫
免疫耐受
抗体
单克隆抗体
效应器
免疫学
作者
K. Satoh,Yoichi Kobayashi,Kaori Fujimaki,Shinko Hayashi,Saori Ishida,Daisuke Sugiyama,Takahiko Sato,Kyungtaek Lim,Megumi Miyamoto,Shiho Kozuma,Michinori Kadokura,Kenichi Wakita,Masato Hata,Kazuki Hirahara,Masato Amano,Ichiro Watanabe,Atsushi Okamoto,Andrea Tuettenberg,Helmut Jonuleit,Atsushi Tanemura
标识
DOI:10.1093/intimm/dxab027
摘要
Regulatory T (Treg) cells, which are essential for maintaining self-tolerance, inhibit anti-tumor immunity, consequently hindering protective cancer immunosurveillance, and hampering effective anti-tumor immune responses in tumor-bearing hosts. Here, we show that depletion of Treg cells via targeting glycoprotein A repetitions predominant (GARP) induces effective anti-tumor immune responses. GARP was specifically expressed by highly suppressive Treg cells in the tumor microenvironment (TME) of multiple cancer types in humans. In the periphery, GARP was selectively induced in Treg cells, but not in effector T cells, by polyclonal stimulation. DS-1055a, a novel afucosylated anti-human GARP monoclonal antibody, efficiently depleted GARP+ Treg cells, leading to the activation of effector T cells. Moreover, DS-1055a decreased FoxP3+CD4+ T cells in the TME and exhibited remarkable anti-tumor activity in humanized mice bearing HT-29 tumors. We propose that DS-1055a is a new Treg-cell-targeted cancer immunotherapy agent with augmentation of anti-tumor immunity.
科研通智能强力驱动
Strongly Powered by AbleSci AI